Qbiotics Group Limited

Qbiotics Group Limited company information, Employees & Contact Information

QBiotics is solving major health issues for humans and companion animals. We discover, develop and commercialise novel pharmaceuticals based on plant-derived cell-signalling molecules sourced from the Australian tropical rainforest, and underpinned by our discovery platform EcoLogic™. We simultaneously develop our products for the human and veterinary markets, delivering early to market veterinary products as well as real world animal data that informs and de-risks early stages of our human programmes. We currently have two leading programmes. The first is an oncology drug, tigilanol tiglate, with activity against a range of solid tumours. Tigilanol tiglate is now registered as a veterinary pharmaceutical, brand name STELFONTA®, and is marketed in the US, EU, UK and Australia. The drug is also currently in human Phase II clinical development. Our second programme is a pharmaceutical, EBC-1013, that addresses all the requirements for healing chronic and acute wounds. We have a very skilled and enthusiastic team of 61 employees.

Company Details

Employees
35
Founded
-
Address
165 Moggill Rd, Taringa,queensland 4068,australia
Phone
+61 7 3870 8933
Email
en****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Cambridge.
HQ
Taringa, Queensland
Looking for a particular Qbiotics Group Limited employee's phone or email?

Qbiotics Group Limited Questions

News

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA - PR Newswire

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA PR Newswire

Tigilanol Tiglate Shows Early Efficacy in Soft Tissue Sarcomas - OncLive

Tigilanol Tiglate Shows Early Efficacy in Soft Tissue Sarcomas OncLive

Brisbane-based QBiotics celebrates 25 years since its creation - BiotechDispatch

Brisbane-based QBiotics celebrates 25 years since its creation BiotechDispatch

ICR and life sciences company QBiotics launch new collaboration to study potential cancer drug derived from rainforest tree species - The Institute of Cancer Research

ICR and life sciences company QBiotics launch new collaboration to study potential cancer drug derived from rainforest tree species The Institute of Cancer Research

Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses - Frontiers

Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses Frontiers

QBiotics wins FDA orphan status for rainforest-derived cancer drug - Clinical Trials Arena

QBiotics wins FDA orphan status for rainforest-derived cancer drug Clinical Trials Arena

QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER - PR Newswire

QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER PR Newswire

“Despite advances, access to innovative treatments can be limited, particularly for rare cancers” - BioSpectrum Asia

“Despite advances, access to innovative treatments can be limited, particularly for rare cancers” BioSpectrum Asia

FDA Grants Orphan Drug Designation to Tigilanol Tiglate in Soft Tissue Sarcoma - OncLive

FDA Grants Orphan Drug Designation to Tigilanol Tiglate in Soft Tissue Sarcoma OncLive

QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA® - PR Newswire

QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA® PR Newswire

Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors - Frontiers

Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors Frontiers

Dr Boreham’s Crucible: Qbiotics hopes to crawl through IPO ‘window of opportunity’ - Stockhead

Dr Boreham’s Crucible: Qbiotics hopes to crawl through IPO ‘window of opportunity’ Stockhead

QBiotics’ STELFONTA® Receives FDA Approval for Canine Mast cell Tumours - The Indian Sun

QBiotics’ STELFONTA® Receives FDA Approval for Canine Mast cell Tumours The Indian Sun

QBiotics says recruitment completed in Phase 2a clinical trial of tigilanol tiglate - BiotechDispatch

QBiotics says recruitment completed in Phase 2a clinical trial of tigilanol tiglate BiotechDispatch

QBiotics joins TDM Growth Partners to accelerate drug development timelines - BioSpectrum Asia

QBiotics joins TDM Growth Partners to accelerate drug development timelines BioSpectrum Asia

Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate - Frontiers

Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate Frontiers

QBiotics announces the appointment of Sergio Duchini to its board - BiotechDispatch

QBiotics announces the appointment of Sergio Duchini to its board BiotechDispatch

QBiotics completes successful $85 million capital raise - BiotechDispatch

QBiotics completes successful $85 million capital raise BiotechDispatch

Rainforest drug-maker Qbiotics wants to raise $26m but it’s not sure when it will list - Stockhead

Rainforest drug-maker Qbiotics wants to raise $26m but it’s not sure when it will list Stockhead

Scientists Find an Australian Berry That Can Cure Cancer in 48 Hours? - Snopes

Scientists Find an Australian Berry That Can Cure Cancer in 48 Hours? Snopes

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma - WhaTech

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma WhaTech

Top Qbiotics Group Limited Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant